Clinical Trials on Ann Arbor Stage II Hodgkin Lymphoma in China

Total 945 results

Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Chinese PLA General Hospital

Unknown

Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Hoffmann-La Roche
Institute of Cancer Research, United Kingdom; German Low Grade Lymphoma Study...

Completed

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Non-Hodgkin's Lymphoma

Italy, Belgium, Canada, United Kingdom, Australia, China, Germany, United States, Russian Federation, Spain, Taiwan, Israel, Czechia, Hungary, Japan, France, Finland, Sweden
Peking University

Recruiting

The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

China
Ruijin Hospital

Unknown

Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma

China
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Not yet recruiting

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
First Affiliated Hospital of Zhejiang University
Hangzhou HeZheng Pharmaceutical Co., Ltd

Unknown

Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma

Lymphoma, B-Cell

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children...

Recruiting

Multi-CAR-T Cells Targeting B Cell Lymphomas

B Cell Lymphoma (BCL)

China
Huiqiang Huang

Recruiting

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma (RIPPLE)

Lymphoma, B-Cell

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma

Lymphoma

China
Chinese PLA General Hospital

Unknown

Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

Primary Mediastinal Large B-cell Lymphoma

China
Chinese PLA General Hospital

Recruiting

TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Non-hodgkin Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital; The First People's Hospital of Hefei; Hefei Binhu...

Unknown

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
Peking University
Marino Biotechnology Co., Ltd.

Unknown

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Relapsed or Refractory B-cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

China
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Recruiting

Biomarker Guided Treatment in DLBCL

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Active, not recruiting

Reduced Chemotherapy in Low Risk DLBCL

Diffuse Large B-cell Lymphoma

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Relapsed or Refractory Peripheral T-Cell Lymphoma

China
Ruijin Hospital

Unknown

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma (DR-CHOP)

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Unknown

Chidamide Plus R-CHOP in Elderly DLBCL

Diffuse Large B-cell Lymphoma

China
Ruijin Hospital

Unknown

A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL

Diffuse Large B-cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Withdrawn

Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Fudan University

Unknown

R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

Relapsed and Refractory B-cell Lymphoma

China
Ruijin Hospital

Not yet recruiting

Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

China
Ruijin Hospital
The First Affiliated Hospital of Nanchang University; Qilu Hospital of Shandong... and other collaborators

Recruiting

The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years

Diffuse Large B-Cell Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

DLBCL

China
Shanghai Institute Of Biological Products

Completed

A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL

Diffuse Large B-Cell Lymphoma

China
Peking University Cancer Hospital & Institute

Unknown

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

China
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Sun Yat-sen University

Recruiting

A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

NK/T Cell Lymphoma Nos

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

Extranodal NK/T-cell Lymphoma, Nasal Type

China
Sun Yat-sen University

Terminated

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Lymphoma, Extranodal NK-T-Cell

China
The First Affiliated Hospital of Xiamen University
Fujian Cancer Hospital; Chinese PLA General Hospital; Jiangxi Provincial Cancer... and other collaborators

Recruiting

Prospective Clinical Study of Obrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

Marginal Zone Lymphoma

China
Henan Cancer Hospital

Not yet recruiting

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Peripheral T Cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Peripheral T Cell Lymphoma

China
Akeso
Akeso Pharmaceuticals, Inc.

Terminated

A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
JHL Biotech, Inc.

Terminated

A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

B Cell Lymphoma

China
Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Unknown

A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL

B-cell Lymphoma

China
Ruijin Hospital

Not yet recruiting

The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma

Extranodal Natural Killer T Cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Chidamide Plus Azacitidine for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Peripheral T Cell Lymphoma | Epigenetic Repression

China
Peking Union Medical College Hospital

Recruiting

Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Intravascular Large B-Cell Lymphoma

China
Cancer Institute and Hospital, Chinese Academy...
Sun Yat-sen University

Unknown

30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy

Lymphoma, Large B-Cell, Diffuse

China
Rong Tao

Recruiting

Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Children's Cancer Group, China

Recruiting

Vinorelbine for Recurrent ALCL-2017

Anaplastic Large Cell Lymphoma | Vinorelbine

China

Clinical Trials on Ann Arbor Stage II Hodgkin Lymphoma in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations